ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - posaconazole 100 mg - posaconazole

ישראל - עברית - Ministry of Health

ofek pharma ltd, israel - posaconazole - טבליות שחרור מושהה - posaconazole 100 mg - posaconazole

ישראל - עברית - Ministry of Health

teva israel ltd - apixaban - טבליות מצופות פילם - apixaban 2.5 mg - apixaban

ישראל - עברית - Ministry of Health

teva israel ltd - apixaban - טבליות מצופות פילם - apixaban 5 mg - apixaban

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - תרכיז להכנת תמיסה לאינפוזיה - posaconazole 300 mg/vial - posaconazole

ישראל - עברית - Ministry of Health

inovamed ltd - posaconazole - טבליות שחרור מושהה - posaconazole 100 mg - posaconazole

ישראל - עברית - Ministry of Health

intervet ( israel) ltd - mometasone furoate (as monohydrate); orbifloxacin; posaconazole - orbifloxacin 8.5 mg/ml; mometasone furoate (as monohydrate) 0.9 mg/ml; posaconazole 0.9 mg/ml

ישראל - עברית - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.